NATCO Pharma Third Quarter 2025 Earnings: Misses Expectations

NATCO Pharma (NSE:NATCOPHARM) Third Quarter 2025 Results

Key Financial Results

• Revenue: ₹6.51b (down 14% from 3Q 2024).
• Net income: ₹1.33b (down 38% from 3Q 2024).
• Profit margin: 20% (down from 28% in 3Q 2024). The decrease in margin was driven by lower revenue.
• EPS: ₹7.43 (down from ₹11.88 in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

NATCO Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 45%. Earnings per share (EPS) also missed analyst estimates by 44%.

Looking ahead, revenue is expected to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 27% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for NATCO Pharma (1 is a bit concerning!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.